SCHEMBL18095925

SCHEMBL18095925

C#Cc1cc(CO)cc(CO)c1

nearest known ligand 0.42

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.42
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
PDK2 Q15119 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CASP6 P55212 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8589719 0.95 ACHE (0.42) ACHECYP1A1CYP1B1PDK2KDM4E
SCHEMBL510419 0.77 FFAR1 (0.46) CYP1A1CYP1B1TSHR
SCHEMBL63159 0.76 ACHE (0.62) ACHEKDM4ECASP6TSHR
SCHEMBL16950926 0.75 ACHE (0.30) ACHE
SCHEMBL14962453 0.75 CYP2A6 (0.40)
SCHEMBL31490567 0.74 CYP1A1 (0.33) CYP1A1CYP1B1TSHR
SCHEMBL4693793 0.74 GRM5 (0.42) ACHEKDM4ECASP6TSHR
SCHEMBL138492 0.74 ACHE (0.42) ACHEKDM4ECASP6TSHR
SCHEMBL516512 0.74 TSHR (0.43) TSHR
SCHEMBL14012242 0.70 ACHE (0.39) ACHEKDM4ECASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025082283-A1 LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE 四川科伦博泰生物医药股份有限公司 2025-04-24 WO disclosed
CN-114195989-B Top anti-reflection coating polymer with trapezoid structure, top anti-reflection coating composition and preparation method thereof 福建泓光半导体材料有限公司 2024-03-15 CN disclosed
CN-114195989-A Top anti-reflection coating polymer with trapezoidal structure, top anti-reflection coating composition and preparation method thereof 福建泓光半导体材料有限公司 2022-03-18 CN disclosed
WO-2020025066-A1 COMPOSITIONS AND METHODS FOR DETECTION AND IMAGING OF AMYLOID FIBRILS, AMYLOID PLAQUES, RNA, AND NUCLEOLI THE UNIVERSITY OF HONG KONG (CN) 2020-02-06 WO disclosed
US-20180094017-A1 OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM GIFU UNIVERSITY (JP) 2018-04-05 US disclosed
US-20180094017-A1 OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM GIFU UNIVERSITY (JP) 2018-04-05 US disclosed
WO-2016152980-A1 OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE 国立大学法人岐阜大学 2016-09-29 WO disclosed
WO-2016152980-A1 OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE 国立大学法人岐阜大学 2016-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180094017-A1 OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM APOB, TTPA, AOX1 ACHE 4564/4885CYP1A1 4250/4885CYP1B1 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.